Iberia Pharmaceuticals, a prominent player in science-driven skincare, has committed INR 70 crore to develop a new state-of-the-art manufacturing and research facility in Jhajjar, Haryana. Spread over 60,000 square feet, the next-generation unit is slated to become operational by mid-2026 and is positioned as a key pillar of the government-backed “Make in India” initiative.
The facility is being designed to deliver high-performance, personalised dermaceutical and wellness products grounded in rigorous science. Equipped with advanced control systems and best-in-class equipment, the plant will support large-scale commercial manufacturing without compromising on international quality standards. Sustainability, compliance, and economic viability are central to its operating philosophy.
Complementing Iberia’s existing discovery and clinical-grade infrastructure—particularly in nanotechnology-enabled skincare and therapeutic solutions—the new unit will house high-tech research laboratories. These labs will enable continuous monitoring of market trends, consumer insights, product innovation, and formulation optimisation based on real-world data.
“At Iberia, we are bringing global manufacturing quality to India, building trust and capacity while raising the standard of healthcare,” said Nitin Jain, founder of Iberia Pharmaceuticals. “This new plant is a major milestone in our growth journey. Fully aligned with global regulatory expectations, it underscores our commitment to scaling responsibly and serving customers across geographies more efficiently. We strongly support the Government of India’s vision of expanding access to affordable world-class healthcare products.”
The facility is expected to create over 600 jobs at full scale and produce more than 12 million units annually across dermatology, wellness, and chronic care categories for both domestic and international markets.
Iberia’s product ethos is rooted in science-backed innovation. “We delve deep into research to deliver precise, safe, and responsible healthcare solutions,” said Saurav Ojha, co-founder. “Leveraging cutting-edge nanotechnology, we are pushing boundaries in dermatological excellence and expanding into adjacent wellness and chronic care domains. This advanced manufacturing and research hub symbolizes that commitment.”
The company’s portfolio includes clinically tested, globally recognised brands such as Sesderma, Mediderma, Dermpix, Noreva, and Metacare. Its audience spans individual consumers seeking skin health improvements, healthcare professionals, and clinical partners.
Originating from a singular vision, Iberia has evolved over decades into a comprehensive dermatology and wellness platform with robust R&D, distribution, and manufacturing capabilities. The new Jhajjar facility reinforces its trajectory toward becoming a trusted, home-grown global manufacturing and innovation hub in dermatological healthcare.
